{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Frio-bravo-qweek.simplecast.com%2Fepisodes%2Fepisode-214-hiv-prep-review-qpVRqnzp","width":444,"version":"1.0","type":"rich","title":"Episode 213: HIV PrEP Review","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/e7f25359-702b-47e8-97f2-d7f32a376648/89b65036-b2fa-4527-9fd4-f80317fd5fc8/rio_bravo_qweek_podcastlogonew.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/fefeb1ca-617d-4a7e-8ef8-615f01b0f41c\" height=\"200\" width=\"100%\" title=\"Episode 213: HIV PrEP Review\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Episode 213: HIV PrEP Review\n\nH. Nicole Magaña, medical student, reviews the history of PrEP and outlines the currently FDA-approved medications used for HIV prevention. Dr. Arreaza provides additional perspective on long-acting injectable options, including how quickly they begin to protect patients after initiation. \n\nWritten by Nicole Magana, MSIV, American University of the Caribbean. Comments and edits by Hector Arreaza, MD.\n"}